Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a developer of oxygen-carrying therapeutics, will present to an audience of principals and key decision makers of broker/dealers and financial firms at the
FSX Investment Conference
to be held at the Ritz Carlton in Fort Lauderdale, Florida from July 25th-27th, 2013. The Company’s interim CEO, President, and CFO Michael Jebsen will present to the FSX audience at 2:15 pm on Thursday, July 25
OXBT’s presentation at FSX coincides with several significant developments. The Company recently
initiated its second cohort of its Phase IIb
clinical trials being conducted in Israel and Switzerland to investigate the safety and tolerability of Oxycyte® in patients with severe, non-penetrating traumatic brain injury. Oxycyte® is a proprietary perfluorocarbon (PFC) emulsion is designed to rapidly deliver oxygen to damaged tissues using small molecule PFCs that can carry up to 4x more O2 and can dissolve the gases twice as fast as normal blood cells. Also, the Company recently reported successful completion of FDA requested immunocompetency studies on Oxycyte®
and their plan to submit
the results from these safety studies to the FDA sometime this month (July). This
preclinical research program is fully-funded by the U.S. Army, and the Company has entered into four additional Cooperative Research and Development Agreements with the U.S. Navy to examine potential therapeutic applications for Oxycyte®. These studies are either completed, underway or being planned for decompression sickness (DCS) and spinal cord injury related to DCS, TBI, hemorrhagic shock, and other wounds.
Mr. Jebsen will also be conducting additional meetings with investors in Florida including Tampa, Naples, and Sarasota on Wednesday July 24
and in West Palm Beach, Boca Raton, and Fort Lauderdale on Thursday, July 25th. Investors interested in 1-on-1 meetings should contact Robert Haag at
The Company’s investor presentation will include:
- An overview of the Company's business model
- A summary of progress with the FDA and Phase 2b testing in Israel and Switzerland
- An update of current scientific results and indications of Oxycyte® efficacy
- A review of its current portfolio of products and applications
- Plans for increasing existing sources of revenue & funding, and an outline for its growth trajectory
- Profiles of its management team and advisors
FSX is the premier investment conference organization in the United States. Founded in 1983, FSX is a national organization comprised of independent FINRA broker/dealer firms. Through a series of regularly scheduled investment conferences, FSX brings these firms together with the purpose of sharing information and showcasing investment opportunities. More information can be found at
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the Company has commercialized its Dermacyte® line of skin care cosmetics for the anti-aging market. Dermacyte is now out-licensed to Valor Cosmetics of Switzerland.